{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:50:43Z","timestamp":1790704243073,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.schres.2019.10.050","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T09:19:43Z","timestamp":1574759983000},"page":"38-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Cerebral glutamate and GABA levels in high-risk of psychosis states: A\u00a0focused review and meta-analysis of 1H-MRS studies"],"prefix":"10.1016","volume":"215","author":[{"given":"Christina","family":"Wenneberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte Yding","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Hjorth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik Johan","family":"Buchardt Zingenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Birkedal","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egill","family":"Rostrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Villumsen","family":"Broberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete","family":"Nordentoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.schres.2019.10.050_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.yco.0000214337.29378.cd","article-title":"What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update","volume":"19","author":"Abbott","year":"2006","journal-title":"Curr. Opin. Psychiatr."},{"issue":"9","key":"10.1016\/j.schres.2019.10.050_bib2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/mp.2012.37","article-title":"Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction","volume":"17","author":"Ayalew","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2019.10.050_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0304-3940(00)01264-7","article-title":"Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study","volume":"289","author":"Block","year":"2000","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.schres.2019.10.050_bib4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.biopsych.2010.11.030","article-title":"Hippocampal glutamate levels and striatal dopamine D(2\/3) receptor occupancy in subjects at ultra high risk of psychosis","volume":"70","author":"Bloemen","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2019.10.050_bib5","first-page":"1","article-title":"Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naive patients with psychosis","author":"Bojesen","year":"2019","journal-title":"Psychol. Med."},{"issue":"4","key":"10.1016\/j.schres.2019.10.050_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4306\/pi.2009.6.4.264","article-title":"Depressive symptoms and brain metabolite alterations in subjects at ultra-high risk for psychosis: a preliminary study","volume":"6","author":"Byun","year":"2009","journal-title":"Psychiatr. Investig."},{"issue":"12","key":"10.1016\/j.schres.2019.10.050_bib7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tics.2015.09.009","article-title":"How schizophrenia develops: cognitive and brain mechanisms underlying onset of psychosis","volume":"19","author":"Cannon","year":"2015","journal-title":"Trends Cogn. Sci."},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.10.050_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2011.05.024","article-title":"Magnetic resonance spectroscopy of limbic structures displays metabolite differences in young unaffected relatives of schizophrenia probands","volume":"131","author":"Capizzano","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.10.050_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fpsyt.2016.00061","article-title":"GABA system in schizophrenia and mood disorders: a mini review on third-generation imaging studies","volume":"7","author":"Chiapponi","year":"2016","journal-title":"Front. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2019.10.050_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1503\/jpn.170201","article-title":"GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study","volume":"44","author":"Da Silva","year":"2019","journal-title":"J.\u00a0Psychiatry Neurosci. : JPN"},{"issue":"9","key":"10.1016\/j.schres.2019.10.050_bib11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/npp.2011.65","article-title":"Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis","volume":"36","author":"de la Fuente-Sandoval","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2019.10.050_bib12","first-page":"1","article-title":"Cortico-striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy","volume":"19","author":"De La Fuente-Sandoval","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2019.10.050_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr. Clin. Trials"},{"issue":"7","key":"10.1016\/j.schres.2019.10.050_bib14","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00330-006-0546-1","article-title":"Proton MR spectroscopy of the brain at 3 T: an update","volume":"17","author":"Di","year":"2007","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.schres.2019.10.050_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fpsyt.2017.00066","article-title":"Effects of antipsychotic administration on brain glutamate in schizophrenia: a systematic review of longitudinal (1)H-MRS studies","volume":"8","author":"Egerton","year":"2017","journal-title":"Front. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2019.10.050_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2217\/npy.11.51","article-title":"An overview of functional, structural and neurochemical imaging studies in individuals with a clinical high risk for psychosis","volume":"1","author":"Egerton","year":"2011","journal-title":"Neuropsychiatry"},{"issue":"11","key":"10.1016\/j.schres.2019.10.050_bib17","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","article-title":"Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE)","volume":"23","author":"Egerton","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2019.10.050_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2174\/138161212799316244","article-title":"Glutamate and psychosis risk","volume":"18","author":"Egerton","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"issue":"6","key":"10.1016\/j.schres.2019.10.050_bib19","doi-asserted-by":"crossref","first-page":"e1147","DOI":"10.1038\/tp.2017.124","article-title":"Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis","volume":"7","author":"Egerton","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2019.10.050_bib20","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1038\/npp.2014.143","article-title":"Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis","volume":"39","author":"Egerton","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2019.10.050_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamapsychiatry.2013.269","article-title":"The psychosis high-risk state: a comprehensive state-of-the-art review","volume":"70","author":"Fusar-Poli","year":"2013","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.schres.2019.10.050_bib22","article-title":"Resting-state gamma-band power alterations in schizophrenia reveal E\/I-balance abnormalities across illness-stages","volume":"7","author":"Grent-\u2019t-Jong","year":"2018","journal-title":"eLife"},{"issue":"5","key":"10.1016\/j.schres.2019.10.050_bib23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/jmri.21936","article-title":"Optimized glutamate detection at 3T","volume":"30","author":"Hancu","year":"2009","journal-title":"J.\u00a0Magn. Reson. Imaging : JMRI"},{"issue":"15","key":"10.1016\/j.schres.2019.10.050_bib24","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1523\/JNEUROSCI.23-15-06315.2003","article-title":"Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia","volume":"23","author":"Hashimoto","year":"2003","journal-title":"J.\u00a0Neurosci. : Off. J. Soc. Neurosci."},{"issue":"7414","key":"10.1016\/j.schres.2019.10.050_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin. Res. Ed.)"},{"issue":"2","key":"10.1016\/j.schres.2019.10.050_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2019.10.050_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neubiorev.2009.07.010","article-title":"Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review","volume":"34","author":"Inta","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.schres.2019.10.050_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0074-7742(06)78003-5","article-title":"Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions","volume":"78","author":"Javitt","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"issue":"1","key":"10.1016\/j.schres.2019.10.050_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.schres.2009.08.012","article-title":"Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study","volume":"115","author":"Keshavan","year":"2009","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2019.10.050_bib30","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1503\/cmaj.121077","article-title":"Reducing all-cause mortality among patients with psychiatric disorders: a population-based study","volume":"185","author":"Kisely","year":"2013","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"3","key":"10.1016\/j.schres.2019.10.050_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"issue":"3","key":"10.1016\/j.schres.2019.10.050_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41386-018-0236-0","article-title":"Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a (1)[H]-spectroscopy twin study","volume":"44","author":"Legind","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2019.10.050_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tins.2011.10.004","article-title":"Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia","volume":"35","author":"Lewis","year":"2012","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2019.10.050_bib34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"10","key":"10.1016\/j.schres.2019.10.050_bib35","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/archneur.63.10.1372","article-title":"Cognitive dysfunction in schizophrenia: convergence of g-aminobutyric acid and glutamate alterations","volume":"63","author":"Lewis","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.schres.2019.10.050_bib36","doi-asserted-by":"crossref","first-page":"21873","DOI":"10.1038\/srep21873","article-title":"Prefrontal NAA and glx levels in different stages of psychotic disorders: a 3T 1H-MRS study","volume":"6","author":"Liemburg","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.schres.2019.10.050_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","article-title":"Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia","volume":"31","author":"Lisman","year":"2008","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.schres.2019.10.050_bib38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/mp.2008.87","article-title":"Proton MRS in twin pairs discordant for schizophrenia","volume":"15","author":"Lutkenhoff","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2019.10.050_bib39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1176\/appi.ajp.2015.15020190","article-title":"Prefrontal GABA levels measured with magnetic resonance spectroscopy in patients with psychosis and unaffected siblings","volume":"173","author":"Marenco","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2019.10.050_bib40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/schbul\/sbr110","article-title":"Early intervention for psychosis","volume":"37","author":"Marshall","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2019.10.050_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tips.2007.11.005","article-title":"Functional neuroimaging in schizophrenia: diagnosis and drug discovery","volume":"29","author":"McGuire","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.schres.2019.10.050_bib42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1134\/S1607672916030029","article-title":"(1)H-MRS and MEGA-PRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients","volume":"468","author":"Menschikov","year":"2016","journal-title":"Dokl. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.schres.2019.10.050_bib43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/archpsyc.64.2.156","article-title":"Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia","volume":"64","author":"Menzies","year":"2007","journal-title":"Arch. Gen. Psychiatr."},{"issue":"7","key":"10.1016\/j.schres.2019.10.050_bib44","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.schres.2019.10.050_bib45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neuroimage.2017.11.026","article-title":"Towards a neurodynamical understanding of the prodrome in schizophrenia","volume":"190","author":"Mikanmaa","year":"2017","journal-title":"Neuroimage"},{"issue":"3","key":"10.1016\/j.schres.2019.10.050_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.tins.2014.12.005","article-title":"Translating the MAM model of psychosis to humans","volume":"38","author":"Modinos","year":"2015","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2019.10.050_bib47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/ijnp\/pyx076","article-title":"Cortical GABA in subjects at ultra-high risk of psychosis: relationship to negative prodromal symptoms","volume":"21","author":"Modinos","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.schres.2019.10.050_bib48","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J.\u00a0Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2019.10.050_bib49","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/schbul\/sbs075","article-title":"Capturing the angel in \"angel dust\": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans","volume":"38","author":"Moghaddam","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2019.10.050_bib50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"issue":"5","key":"10.1016\/j.schres.2019.10.050_bib51","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/schbul\/sbt124","article-title":"Reduced frontal glutamate\u00a0+ glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia","volume":"40","author":"Natsubori","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.schres.2019.10.050_bib52","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.euroneuro.2015.05.005","article-title":"Associations of hippocampal metabolism and regional brain grey matter in neuroleptic-naive ultra-high-risk subjects and first-episode schizophrenia","volume":"25","author":"Nenadic","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2019.10.050_bib53","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.schres.2019.10.050_bib54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2016.05.013","article-title":"Thalamo-cortical communication, glutamatergic neurotransmission and neural oscillations: a unique window into the origins of ScZ?","volume":"180","author":"Pratt","year":"2017","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2019.10.050_bib55","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/mrm.1910300604","article-title":"Estimation of metabolite concentrations from localized in\u00a0vivo proton NMR spectra","volume":"30","author":"Provencher","year":"1993","journal-title":"Magn. Reson. Med."},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.10.050_bib56","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2007.11.028","article-title":"Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia","volume":"99","author":"Purdon","year":"2008","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.schres.2019.10.050_bib57","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/nbm.3045","article-title":"Glutamate and glutamine: a review of in\u00a0vivo MRS in the human brain","volume":"26","author":"Ramadan","year":"2013","journal-title":"NMR Biomed."},{"issue":"2","key":"10.1016\/j.schres.2019.10.050_bib58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/08039480801984008","article-title":"Early detection and intervention of psychosis","volume":"62","author":"Salokangas","year":"2008","journal-title":"Rev. Nord. J. Psychiatr."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.schres.2019.10.050_bib59","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1007\/s00406-012-0360-5","article-title":"Multimodal functional and structural imaging investigations in psychosis research","volume":"262","author":"Schultz","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"11","key":"10.1016\/j.schres.2019.10.050_bib60","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/s41386-018-0163-0","article-title":"Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis","volume":"443","author":"Shakory","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2019.10.050_bib61","first-page":"24","article-title":"Information processing and brain metabolic characteristics in patients at ultra-high risk for endogenous psychosis. [Russian]. Zhurnal Nevrologii i Psihiatrii imeni S","volume":"2015","author":"Shendyapina","year":"2015","journal-title":"S\u00a0Korsakova"},{"issue":"4","key":"10.1016\/j.schres.2019.10.050_bib62","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2174\/138161212799316262","article-title":"Ethical implications for clinical practice and future research in \"at risk\" individuals","volume":"18","author":"Singh","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"issue":"1","key":"10.1016\/j.schres.2019.10.050_bib63","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jmr.2009.12.002","article-title":"Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7T","volume":"203","author":"Snyder","year":"2010","journal-title":"J.\u00a0Mag. Reson."},{"issue":"22","key":"10.1016\/j.schres.2019.10.050_bib64","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.2174\/138161209788957438","article-title":"Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia","volume":"15","author":"Stone","year":"2009","journal-title":"Curr. Pharmaceut. Des."},{"issue":"6","key":"10.1016\/j.schres.2019.10.050_bib65","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.biopsych.2009.05.006","article-title":"Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume","volume":"66","author":"Stone","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2019.10.050_bib66","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0269881106073126","article-title":"Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review","volume":"21","author":"Stone","year":"2007","journal-title":"J.\u00a0Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.10.050_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2013.05.024","article-title":"Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy","volume":"148","author":"Tandon","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.10.050_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \"just the facts\" 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2019.10.050_bib69","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.biopsych.2016.04.007","article-title":"7T proton magnetic resonance spectroscopy of gamma-aminobutyric acid, glutamate, and glutamine reveals altered concentrations in patients with schizophrenia and healthy siblings","volume":"81","author":"Thakkar","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2019.10.050_bib70","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1176\/appi.ajp.161.6.1116","article-title":"3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia","volume":"161","author":"Tibbo","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.10.050_bib71","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.schres.2016.01.005","article-title":"Are there glutamate abnormalities in subjects at high risk mental state for psychosis? A review of the evidence","volume":"171","author":"Treen","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2019.10.050_bib72","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.schres.2010.02.1048","article-title":"Altered medial temporal activation related to local glutamate in subjects with prodromal signs of psychosis","volume":"117","author":"Valli","year":"2010","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.10.050_bib73","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.schres.2013.07.004","article-title":"Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups","volume":"149","author":"van der Gaag","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2019.10.050_bib74","doi-asserted-by":"crossref","first-page":"3915703","DOI":"10.1155\/2016\/3915703","article-title":"Reduced gamma-aminobutyric acid and Glutamate+Glutamine levels in drug-naive patients with first-episode schizophrenia but not in those at ultrahigh risk","volume":"2016","author":"Wang","year":"2016","journal-title":"Neural Plast."},{"issue":"1","key":"10.1016\/j.schres.2019.10.050_bib75","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuroimage.2010.04.012","article-title":"Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study","volume":"52","author":"Wood","year":"2010","journal-title":"Neuroimage"},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.10.050_bib76","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.schres.2009.03.036","article-title":"Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus","volume":"111","author":"Yoo","year":"2009","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2019.10.050_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2010.03.014","article-title":"The psychosis threshold in Ultra High Risk (prodromal) research: is it valid?","volume":"120","author":"Yung","year":"2010","journal-title":"Schizophr. Res."},{"issue":"33","key":"10.1016\/j.schres.2019.10.050_bib78","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/S0007125000297602","article-title":"Prediction of psychosis. A step towards indicated prevention of schizophrenia","volume":"Supplement 172","author":"Yung","year":"1998","journal-title":"Br. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2019.10.050_bib79","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0920-9964(03)00192-0","article-title":"Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features","volume":"67","author":"Yung","year":"2004","journal-title":"Schizophr. Res."},{"issue":"11\u201312","key":"10.1016\/j.schres.2019.10.050_bib80","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/j.1440-1614.2005.01714.x","article-title":"Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states","volume":"39","author":"Yung","year":"2005","journal-title":"Aust. N. Z. J. Psychiatr."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419304852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996419304852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:34:47Z","timestamp":1760297687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996419304852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":80,"alternative-id":["S0920996419304852"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2019.10.050","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebral glutamate and GABA levels in high-risk of psychosis states: A\u00a0focused review and meta-analysis of 1H-MRS studies","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2019.10.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}